Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

Market Cap	6.68B -29.7%
Revenue (ttm)	794.80M -0.8%
Net Income	108.03M -49.4%
EPS	0.13 -47.2%
Shares Out	825.10M
PE Ratio	60.33
Forward PE	n/a
Dividend	0.06 (0.78%)
Ex-Dividend Date	Jul 17, 2026

Volume	11,664,937
Open	8.27
Previous Close	8.35
Day's Range	7.99 - 8.34
52-Week Range	7.15 - 12.51
Beta	-0.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About SHA:603229

Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 1,328
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603229

Financial Performance

In 2025, SHA:603229's revenue was 792.76 million, a decrease of -0.32% compared to the previous year's 795.29 million. Earnings were 130.57 million, a decrease of -36.86%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error